R Reshef

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease
    Ran Reshef
    Abramson Cancer Center and the Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    N Engl J Med 367:135-45. 2012
  2. ncbi Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★)
    R Reshef
    Abramson Cancer Center Department of Biostatistics and Epidemiology Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Am J Transplant 11:336-47. 2011
  3. ncbi Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients
    R Reshef
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
    Am J Transplant 11:817-25. 2011
  4. ncbi Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHD
    A Rager
    Division of Hematology Oncology, Blood and Marrow Transplant Program, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Bone Marrow Transplant 46:430-5. 2011
  5. ncbi High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT
    R Tizon
    Blood and Marrow Transplant Program, Division of Hematology Oncology, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Bone Marrow Transplant 47:1332-7. 2012

Detail Information

Publications5

  1. ncbi Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease
    Ran Reshef
    Abramson Cancer Center and the Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    N Engl J Med 367:135-45. 2012
    ..The chemokine receptor CCR5 appears to play a role in alloreactivity. We tested whether CCR5 blockade would be safe and limit GVHD in humans...
  2. ncbi Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★)
    R Reshef
    Abramson Cancer Center Department of Biostatistics and Epidemiology Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Am J Transplant 11:336-47. 2011
    ..Patients with none or one of these factors had a 3-year overall survival of 100% and 79%, respectively. These findings support the use of RI alone in low-risk PTLD and suggest factors that predict response and survival...
  3. ncbi Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients
    R Reshef
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
    Am J Transplant 11:817-25. 2011
    ..These findings demonstrate the importance of HLA polymorphisms in modulating the risk for PTLD, and may be useful in risk stratification and development of monitoring and prophylaxis strategies...
  4. ncbi Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHD
    A Rager
    Division of Hematology Oncology, Blood and Marrow Transplant Program, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Bone Marrow Transplant 46:430-5. 2011
    ..This retrospective analysis suggests that combination anti-cytokine therapy with daclizumab/infliximab has significant activity in SR-GVHD, but outcomes remain poor. New methods to prevent and treat GVHD are urgently needed...
  5. ncbi High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT
    R Tizon
    Blood and Marrow Transplant Program, Division of Hematology Oncology, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Bone Marrow Transplant 47:1332-7. 2012
    ..However, outcomes remain limited in both groups, highlighting the need for more effective interventions to treat early and late complications of IPS...